Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tuberculosis subunit vaccines: from basic science to clinical testing.

T Mark Doherty1, Jes Dietrich, Rolf Billeskov

  • 1Statens Serum Institute, Department of Infectious Disease Immunology, Copenhagen, Denmark. TMD@ssi.dk

Expert Opinion on Biological Therapy
|October 6, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CD8<sup>+</sup> T cell responses recognizing immunodominant <i>Chlamydia</i> antigens fail to protect against infection.

iScience·2026
Same author

Post-exposure vaccine protection of CTH522/CAF<sup>®</sup>01 against reinfection with Chlamydia trachomatis requires Th1/Th17 but not Th2-immunity.

NPJ vaccines·2025
Same author

Age-related changes in the immune system and challenges for the development of age-specific vaccines.

Annals of medicine·2025
Same author

Role of new vaccinators/pharmacists in life-course vaccination.

Annals of medicine·2024
Same author

Burden of vaccine-preventable diseases in adults (50+) in the United States: a retrospective claims analysis.

BMC public health·2024
Same author

Intradermal administration of novel particulate Chlamydia trachomatis vaccine candidates drives protective immune responses.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2024
Same journal

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Expert opinion on biological therapy·2026
Same journal

Type 2 inflammation and biologics: a twenty-year journey.

Expert opinion on biological therapy·2026
Same journal

Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis.

Expert opinion on biological therapy·2026
Same journal

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.

Expert opinion on biological therapy·2026
Same journal

Biological drugs for the treatment of children with atopic dermatitis.

Expert opinion on biological therapy·2026
Same journal

Optimizing biologic therapy in psoriasis: dose adjustment, treatment duration, and tapering-an expert perspective.

Expert opinion on biological therapy·2026
See all related articles

New tuberculosis (TB) vaccines, utilizing proteomics and genomics, are in clinical trials after 80 years. Researchers review these novel subunit vaccines and discuss challenges in TB vaccine development.

Area of Science:

  • Vaccinology
  • Infectious Diseases
  • Immunology

Background:

  • Bacillus Calmette-Guérin (BCG) remains the only licensed tuberculosis vaccine.
  • Significant advancements in proteomics and genomics have enabled the development of new TB vaccine candidates.

Purpose of the Study:

  • To review current tuberculosis vaccines in clinical trials.
  • To discuss novel approaches in stimulating immunity against Mycobacterium tuberculosis.
  • To highlight challenges and strategies in TB vaccine development.

Main Methods:

  • Review of recombinant subunit vaccines for tuberculosis.
  • Analysis of antigen selection based on proteomics and genomics.
  • Evaluation of novel delivery systems for TB vaccine candidates.

Related Experiment Videos

Main Results:

  • Several new tuberculosis vaccines are progressing through Phase I clinical trials.
  • Recombinant subunit vaccines represent a promising new strategy for TB prevention.

Conclusions:

  • Despite progress, significant hurdles remain for the registration of new TB vaccines.
  • Understanding host immune recognition is crucial for effective TB vaccine design.
  • Continued research and development are essential to combat tuberculosis.